Jérôme Desrame

3.6k total citations · 1 hit paper
106 papers, 1.4k citations indexed

About

Jérôme Desrame is a scholar working on Oncology, Surgery and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Jérôme Desrame has authored 106 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 48 papers in Oncology, 40 papers in Surgery and 34 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Jérôme Desrame's work include Colorectal Cancer Treatments and Studies (24 papers), Pancreatic and Hepatic Oncology Research (20 papers) and Cancer Genomics and Diagnostics (12 papers). Jérôme Desrame is often cited by papers focused on Colorectal Cancer Treatments and Studies (24 papers), Pancreatic and Hepatic Oncology Research (20 papers) and Cancer Genomics and Diagnostics (12 papers). Jérôme Desrame collaborates with scholars based in France, Switzerland and Italy. Jérôme Desrame's co-authors include Dominique Béchade, Christophe Louvet, Thierry André, Thomas Aparicio, David Tougeron, Julien Taı̈eb, Christophe Tournigand, C Duvic, Julie Henriques and Astrid Lièvre and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Jérôme Desrame

93 papers receiving 1.4k citations

Hit Papers

Neoadjuvant Nivolumab Plus Ipilimumab and Adjuvant Nivolu... 2022 2026 2023 2024 2022 50 100 150 200
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Neoadjuvant Nivolumab Plus Ipilimumab and Adjuvant Nivolumab in Localized Deficient Mismatch Repair/Microsatellite Instability–High Gastric or Esophagogastric Junction Adenocarcinoma: The GERCOR NEONIPIGA Phase II Study
    2022 220 citations Thierry André, David Tougeron et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jérôme Desrame France 20 762 601 596 250 209 106 1.4k
Faysal Dane Türkiye 19 757 1.0× 303 0.5× 484 0.8× 172 0.7× 164 0.8× 131 1.3k
P. Kienle Germany 21 1.0k 1.4× 845 1.4× 359 0.6× 180 0.7× 274 1.3× 73 1.7k
S Houry France 23 918 1.2× 966 1.6× 717 1.2× 129 0.5× 288 1.4× 70 1.7k
Mahesh Goel India 19 852 1.1× 895 1.5× 823 1.4× 99 0.4× 103 0.5× 175 1.6k
Takuto Hikichi Japan 19 623 0.8× 775 1.3× 560 0.9× 90 0.4× 63 0.3× 183 1.4k
Ludger Staib Germany 24 1.2k 1.6× 581 1.0× 430 0.7× 190 0.8× 221 1.1× 73 1.8k
Hervé Perrier France 18 627 0.8× 522 0.9× 504 0.8× 161 0.6× 132 0.6× 63 1.3k
Elena Manilich United States 17 881 1.2× 819 1.4× 254 0.4× 75 0.3× 431 2.1× 30 1.7k
Byung Chang Kim South Korea 24 1.1k 1.5× 709 1.2× 729 1.2× 127 0.5× 182 0.9× 110 1.8k
Danny Yakoub United States 21 535 0.7× 860 1.4× 712 1.2× 145 0.6× 74 0.4× 81 1.5k

Countries citing papers authored by Jérôme Desrame

Since Specialization
Citations

This map shows the geographic impact of Jérôme Desrame's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jérôme Desrame with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jérôme Desrame more than expected).

Fields of papers citing papers by Jérôme Desrame

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jérôme Desrame. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jérôme Desrame. The network helps show where Jérôme Desrame may publish in the future.

Co-authorship network of co-authors of Jérôme Desrame

This figure shows the co-authorship network connecting the top 25 collaborators of Jérôme Desrame. A scholar is included among the top collaborators of Jérôme Desrame based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jérôme Desrame. Jérôme Desrame is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Bachet, Jean‐Baptiste, Déwi Vernerey, Christophe Boisson, et al.. (2024). 532P G-CSF secondary prophylaxis in patients (pts) with metastatic colorectal cancer (mCRC) treated with trifluridine/tipiracil (FTD/TPI): The GERCOR LONGBOARD study. Annals of Oncology. 35. S447–S447. 1 indexed citations
2.
3.
Borg, Christophe, V. Vendrely, Thierry André, et al.. (2023). 651P DCF versus doublet chemotherapy as first-line treatment of advanced squamous anal cell carcinoma: A multicenter propensity score matching study. Annals of Oncology. 34. S456–S457. 1 indexed citations
4.
André, Thierry, David Tougeron, Guillaume Piessen, et al.. (2022). Neoadjuvant Nivolumab Plus Ipilimumab and Adjuvant Nivolumab in Localized Deficient Mismatch Repair/Microsatellite Instability–High Gastric or Esophagogastric Junction Adenocarcinoma: The GERCOR NEONIPIGA Phase II Study. Journal of Clinical Oncology. 41(2). 255–265. 220 indexed citations breakdown →
5.
Taı̈eb, Julien, Valérie Taly, Julie Henriques, et al.. (2021). Prognostic Value and Relation with Adjuvant Treatment Duration of ctDNA in Stage III Colon Cancer: a Post Hoc Analysis of the PRODIGE-GERCOR IDEA-France Trial. Clinical Cancer Research. 27(20). 5638–5646. 71 indexed citations
6.
Phelip, Jean–Marc, Jérôme Desrame, Julien Edeline, et al.. (2020). 52P Modified FOLFIRINOX versus CISGEM as first-line chemotherapy for advanced biliary tract cancer: Results of AMEBICA PRODIGE 38 randomized phase II trial. Annals of Oncology. 31. S260–S261. 11 indexed citations
7.
Pernot, Simon, Karine Le Malicot, Florence Mary, et al.. (2020). Aflibercept in Combination With FOLFIRI as First-line Chemotherapy in Patients With Metastatic Colorectal Cancer (mCRC): A Phase II Study (FFCD 1302). Clinical Colorectal Cancer. 19(4). 285–290. 6 indexed citations
8.
9.
Taı̈eb, Julien, Franck Bonnetain, Laurent Mineur, et al.. (2017). Three versus six months’ adjuvant oxaliplatin-based chemotherapy for patients with stage III colon cancer: Per-protocol, subgroups and long-lasting neuropathy results. Annals of Oncology. 28. v158–v158. 9 indexed citations
10.
Bibeau, Frédéric, Pascal Artru, Jérôme Desrame, et al.. (2016). P-156 Pathologic response of liver metastases from colorectal cancer after chemotherapy and aflibercept: initial report of 23 cases from 9 patients. Annals of Oncology. 27. ii46–ii46. 1 indexed citations
11.
Béchade, Dominique, et al.. (2008). Syndrome de Mirizzi. La Presse Médicale. 31(5). 217–217.
12.
Béchade, Dominique, et al.. (2008). Polypes coliques juvéniles sporadiques de l’adulte. Gastroentérologie Clinique et Biologique. 33(1). 88–91. 1 indexed citations
13.
Bordier, L., et al.. (2008). Hypercalcémie humorale révélant un lymphome malin non hodgkinien. Annales d Endocrinologie. 69(1). 58–62. 2 indexed citations
14.
Béchade, Dominique, et al.. (2008). Secretory diarrhoea with high faecal potassium concentrations: A new mechanism of diarrhoea associated with colonic pseudo-obstruction? Report of five patients. Gastroentérologie Clinique et Biologique. 32(4). 401–404. 9 indexed citations
15.
Desrame, Jérôme, et al.. (2007). Diagnostic des anémies au cours des cirrhoses alcooliques. La Revue de Médecine Interne. 28(11). 756–765. 6 indexed citations
16.
Béchade, Dominique, et al.. (2006). Thrombose veineuse cérébrale et rectocolite hémorragique. La Revue de Médecine Interne. 27(12). 958–961. 8 indexed citations
17.
Desrame, Jérôme, et al.. (2006). Métastases endobronchiques d’un adénocarcinome rectal. La Presse Médicale. 35(6). 983–984.
18.
Bonnet, S., Dominique Béchade, Laurent Palazzo, et al.. (2005). Ponction sous échoendoscopie d’un cystadénome hépatique. Gastroentérologie Clinique et Biologique. 29(5). 607–609.
19.
Béchade, Dominique, et al.. (2005). Ulcère œsophagien secondaire à la prise de bacampicilline. La Presse Médicale. 34(4). 299–300. 2 indexed citations
20.
Desrame, Jérôme, et al.. (2005). Une cause rare de lombosciatique. La Revue de Médecine Interne. 27(6). 494–496. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Faysal Dane Breakdown of academic impact, for papers by P. Kienle Breakdown of academic impact, for papers by S Houry Breakdown of academic impact, for papers by Mahesh Goel Breakdown of academic impact, for papers by Takuto Hikichi Breakdown of academic impact, for papers by Ludger Staib Breakdown of academic impact, for papers by Hervé Perrier Breakdown of academic impact, for papers by Elena Manilich Breakdown of academic impact, for papers by Byung Chang Kim Breakdown of academic impact, for papers by Danny Yakoub
Rankless by CCL
2026